Is ARNA or XYLD a better dividend investment in 2026?

ARNA currently yields 2.00% with a 5% 5-year dividend growth rate. XYLD yields 10.98% with 0.5% growth. The better choice depends on your goal: XYLD offers higher current income.

What is the dividend yield difference between ARNA and XYLD?

ARNA has a forward dividend yield of 2.00% ($2.00/share annually). XYLD yields 10.98% ($4.30/share annually). The yield gap is 8.98 percentage points.

Home › Compare › ARNA vs XYLD

ARNA vs XYLD: Dividend Comparison 2026

ARNA yields 2.00% · XYLD yields 10.98%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 XYLD wins by $2.7K in total portfolio value· pulled ahead in Year 5

INVESTMENT

TIME HORIZON10 years

ARNA

● Live price

2.00%

Share price

$99.99

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.6K

Annual income

$227.64

Full ARNA calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

10.98%

Share price

$39.13

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.3K

Annual income

$3,219.02

Full XYLD calculator →

Portfolio growth — ARNA vs XYLD

📍 XYLD pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ARNA	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ARNA + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ARNA pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARNA

Annual income on $10K today (after 15% tax)

$170.02/yr

After 10yr DRIP, annual income (after tax)

$193.49/yr

XYLD

Annual income on $10K today (after 15% tax)

$933.63/yr

After 10yr DRIP, annual income (after tax)

$2,736.17/yr

At 15% tax rate, XYLD beats the other by $2,542.67/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARNA + XYLD for your $10,000?

ARNA: 50%XYLD: 50%

100% XYLD50/50100% ARNA

Portfolio after 10yr

$23.9K

Annual income

$1,723.33/yr

Blended yield

7.20%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARNA right now

ARNA

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$94.00

-6.0% upside vs current

Range: $90.00 — $100.00

XYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARNA buys

XYLD buys

No recent congressional trades found for ARNA or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricARNAXYLD

Forward yield	2.00%	10.98% ✓
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$22.6K	$25.3K ✓
Annual income after 10y	$227.64	$3,219.02 ✓
Total dividends collected	$2.1K	$19.6K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: ARNA vs XYLD ($10,000, DRIP)

Year	ARNA Portfolio	ARNA Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1	$10,900	$200.02	$10,818	$1,098.39	+$82.00 → ARNA
2	$11,867	$203.76	$11,738	$1,222.51	+$129.00 → ARNA
3	$12,905	$207.32	$12,774	$1,364.64	+$131.00 → ARNA
4	$14,019	$210.70	$13,944	$1,527.86	+$75.00 → ARNA
5← crossover	$15,214	$213.92	$15,270	$1,715.87	$56.00 → XYLD
6	$16,496	$216.97	$16,775	$1,933.09	$279.00 → XYLD
7	$17,871	$219.86	$18,490	$2,184.87	$619.00 → XYLD
8	$19,344	$222.60	$20,450	$2,477.63	$1.1K → XYLD
9	$20,923	$225.19	$22,697	$2,819.19	$1.8K → XYLD
10	$22,616	$227.64	$25,280	$3,219.02	$2.7K → XYLD

ARNA vs XYLD: Complete Analysis 2026

ARNA — Stock

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Full ARNA Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this ARNA vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARNA vs SCHD ARNA vs JEPI ARNA vs O ARNA vs KO ARNA vs MAIN ARNA vs QYLD ARNA vs JEPQ ARNA vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.